9:58 PM
Sep 21, 2017
 |  BioCentury  |  Finance

Mining fungi

Why GV backed LifeMine's $55M series A

Through GV, LifeMine Therapeutics Inc. will have access to big data expertise as it builds out its fungal DNA mining capabilities.

LifeMine raised $55 million in a series A round on Sept. 18 led by existing investor WuXi Healthcare Ventures. New investors GV, Foresite Capital, Arch Venture Partners, Boyu Capital, Blue Pool Capital, MRL Ventures Fund and Alexandria Venture Investments also participated.

LifeMine's drug discovery platform mines fungal genomes to identify small molecules against previously undruggable targets.

"On average, each...

Read the full 393 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >